Citius Pharmaceuticals, Inc.

Listed Company

CTXRCIK 0001506251NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsNevadaFY ends Sep 30

Period

FY 2025

Revenue

—

Net Income

$-39.74M

Total Assets

$130.94M

Equity

$67.55M

Shares Out

22.38M

Op. Cash Flow

$-26.55M

Business

Citius Pharmaceuticals, Inc. develops and commercializes critical care and oncology-focused biopharmaceutical products that repurpose or reformulate existing agents to address unmet medical needs with reduced development risk. Its main products and candidates include LYMPHIR (denileukin diftitox) for cutaneous T‑cell lymphoma, Mino‑Lok for catheter‑related bloodstream infection catheter salvage, Halo‑Lido topical therapy for hemorrhoids, and NoveCite mesenchymal stem cell therapies for ARDS. Key business units include its majority‑owned commercial subsidiary Citius Oncology, a NoveCite subsidiary for cell therapy, and internal development programs. The company primarily targets U.S. hospital, oncology and critical‑care channels and uses distributor and third‑party commercial partners for domestic and selected international access.

Summary from filing dated 2025-12-23

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Revenues	—	—	—	—	—
Research and development	9	12	15	18	12
General and administrative	19	18	15	12	10
Stock-based compensation general and administrative	11	12	7	4	1
Total Operating Expenses	39	42	37	33	24
Operating Loss	−39	−42	−37	−33	−24
Interest income	110,081	758,000	1	251,399	261,825
Interest expense	−267,782	—	—	—	—
Gain on sale of New Jersey net operating losses	—	2	—	—	—
Total Other Income (Expense), Net	−157,701	3	5	251,399	477,460
Loss before Income Taxes	−39	−39	−32	−33	−23
Income tax expense	1	576,000	576,000	576,000	—
Net Loss	−40	−39	−33	—	—
Net loss attributable to non-controlling interest	2	287,000	—	—	—
Deemed dividend on warrant extension	—	−1	−1	—	—
Net Loss Applicable to Common Stockholders	−37	−40	−34	−34	−25
Net Loss Per Share Applicable to Common Stockholders - Basic (in Dollars per share)	−3.38	−5.97	−5.57	−0.23	−0.23
Net Loss Per Share Applicable to Common Stockholders - Diluted (in Dollars per share)	−3.38	−5.97	−5.57	−0.23	−0.23
Basic (in Shares)	11	7	6	146	109
Diluted (in Shares)	11	7	6	146	109

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Cash and cash equivalents	4	3	26	42	70
Inventory	22	8	—	—	—
Prepaid expenses	1	3	8	3	3
Total Current Assets	28	14	34	45	73
Operating lease right-of-use asset, net	818,694	246,247	454,426	646,074	822,828
Deposits	38,062	38,062	38,062	—	—
In-process research and development	93	93	59	59	59
Goodwill	9	9	9	9	9
Total Other Assets	102	102	69	—	—
Total Assets	131	117	104	114	142
Accounts payable	14	5	3	1	1
License payable	23	28	—	—	—
Accrued expenses	4	17,027	476,300	1	621,960
Accrued compensation	3	2	2	2	2
Note payable	1	—	—	—	—
Operating lease liability	88,348	241,547	218,380	196,989	177,237
Total Current Liabilities	45	36	6	5	4
Deferred tax liability	8	7	6	6	5
Operating lease liability non current	724,925	21,318	262,865	481,245	678,234
Total Liabilities	53	43	12	11	10
Commitments and Contingencies	—	—	—	—	—
Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding	—	—	—	—	—
Common stock - $0.001 par value; 250,000,000 and 16,000,000 shares authorized at September 30, 2025 and 2024, respectively; 18,067,744 and 7,247,243 shares issued and outstanding at September 30, 2025 and 2024, respectively	18,068	7,247	6,354	146,211	145,979
Additional paid-in capital	306	271	253	232	228
Accumulated deficit	−239	−201	−162	−130	−96
Total Citius Pharmaceuticals, Inc. Stockholders Equity	68	70	91	103	132
Non-controlling interest	10	4	600,380	600,380	600,380
Total Equity	78	74	91	103	133
Total Liabilities and Equity	131	117	104	114	142

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Issuance of common stock for services	26,600	284,176	102,000	378,204	—
Amortization of operating lease right-of-use asset	214,250	208,179	191,648	176,754	163,376
Depreciation	—	1,432	2,668	2,923	1,492
Deferred income tax expense	1	576,000	576,000	576,000	—
Inventory	−13	−2	—	—	—
Prepaid expenses	−64,210	−945,389	−5	−111,176	−3
Accounts payable	9	2	2	−111,717	−579,140
Accrued expenses	4	−459,273	−929,094	783,434	457,920
Accrued compensation	1	72,035	—	—	—
Operating lease liability	−236,289	−218,380	−196,989	−177,237	−158,999
Net Cash Used In Operating Activities	−27	−28	−29	−28	−24
License payment	−6	−5	—	—	—
Net Cash Used In Investing Activities	−6	−5	—	—	−40
Proceeds from note payable and advance from employee	1	—	—	—	500
Repayment of advance from employee	−300,000	—	—	—	—
Merger, net	—	−4	—	—	—
Net proceeds from common stock offerings	32	14	—	—	500
Net Cash Provided By Financing Activities	33	10	14	—	120
Net Change in Cash and Cash Equivalents	1	−23	−15	−28	56
IPR&D Milestones included in License Payable	—	28	—	—	—
Net Prepaid Manufacturing transferred to Inventory	1	6	—	—	—
Operating lease right-of-use asset and liability recorded	786,697	—	—	—	—
Interest paid	187,389	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro